Anti-Tau Antibodies for Specific Pathological Tau Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches targeting Tau protein for neurodegenerative disorders such as Alzheimer's Disease and frontotemporal dementia lack specificity and efficacy, as they primarily focus on inhibiting kinases or blocking cytoplasmic aggregation of hyper-phosphorylated Tau protein.
Innovation Solution
Development of anti-Tau antibodies that bind to monomeric, oligomeric, non-phosphorylated, and phosphorylated Tau, with specific epitope recognition, including antibodies with defined heavy and light chain variable regions, to target pathological Tau conformers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic approaches target kinases or block cytoplasmic aggregation of hyper-phosphorylated Tau protein, then the treatment addresses Tau-related pathology, but the approaches lack specificity and efficacy
Solution Approach 1:
The patent develops antibodies with highly specific epitope recognition that target distinct regions of Tau protein (N-terminal, mid-domain, C-terminal regions). Each antibody is engineered to bind specific conformational states or post-translational modification patterns of Tau, providing localized and selective intervention against pathological Tau while preserving normal Tau function. This local quality approach resolves the contradiction by enabling specific targeting of pathological forms without broad inhibition of Tau-related pathways.
Solution Approach 2:
The invention utilizes antibodies that recognize Tau proteins based on specific parameters such as phosphorylation status, conformational state (monomeric vs. oligomeric), and epitope location. By changing the recognition parameters from broad kinase inhibition to specific conformational recognition, the antibodies achieve both high specificity for pathological Tau and high efficacy in neutralizing toxic conformers while sparing normal Tau function.
2Adaptability or versatility
If antibodies bind to multiple forms of Tau (monomeric, oligomeric, phosphorylated, non-phosphorylated), then the therapeutic coverage is broader, but the antibody design complexity increases
Solution Approach 1:
The patent employs a panel of antibodies, each designed with universal applicability to recognize different pathological forms of Tau. These antibodies can be used individually or in combination depending on the specific disease context and Tau pathology present. The multi-functional antibody design allows a single therapeutic platform to address diverse Tauopathies including Alzheimer's disease, frontotemporal dementia, and other tau-related neurodegenerative disorders, achieving broad therapeutic coverage without requiring entirely different antibody designs for each condition.
Data Source
AI summary
The invention provides anti-Tau antibodies and methods of using the same.